BACKGROUND: Lymphangioleiomyomatosis (LAM) is a destructive lung disease of women caused by proliferation of neoplastic-like LAM cells, with mutations in the TSC1/2 tumor suppressor genes. Based on case reports, levels of cancer antigen 125 (CA-125), an ovarian cancer biomarker, can be elevated in patients with LAM. We hypothesized that elevated serum CA-125 levels seen in some patients with LAM were due to LAM, not other malignancies, and might respond to sirolimus treatment.
Lymphangioleiomyomatosis (LAM), a multi-system, low-grade neoplasm primarily found in women, is characterized by cystic lung destruction with impairment of pulmonary function, abdominal tumors, and lymphatic abnormalities.
1,2 LAM may be sporadic or associated with tuberous sclerosis complex (TSC). LAM lung lesions include neoplastic smooth muscle-like LAM cells with mutations in TSC1 (hamartin) and/or TSC2 (tuberin) genes. Hamartin and tuberin form a complex that is a negative regulator of the mechanistic target of rapamycin (mTOR). 3 mTOR is found in two complexes: mTORC1 and mTORC2. mTORC1 coordinates growth factor signals and nutrient availability affecting cell proliferation, cell size, autophagy, and other critical biological processes. Dysfunction of the TSC1/TSC2 complex results in constitutive activation of mTORC1, resulting in abnormal growth of LAM cells. 4 Sirolimus, an immunosuppressive agent, binds to mTOR in the presence of FK506-binding protein 1A, 12 kDa and inhibits the mTORC1 pathway. 5 In LAM, sirolimus is effective in stabilizing lung function, 6 reducing the size of angiomyolipomas (AMLs), 7 and reducing or resolving chylothoraces, chylous infiltration of the lung parenchyma, and lymphangioleiomyomas (LLMs). 8, 9 Cancer antigen 125 (CA-125) was identified as overexpressed in ovarian cancer. 10 CA-125 is a type I transmembrane protein 11 expressed on the epithelial surface lining of multiple organs, including the respiratory tract. 12 As a major component of mucus, 13 CA-125 protects the surface lining of internal organs from pathogens 14, 15 and serves as a biomarker and survival predictor in ovarian cancer. 10 A chemotherapeutic response in ovarian cancer is associated with a decrease in serum CA-125 levels. 16 Abnormally high expression of serum CA-125 is also seen in breast, 17 lung, 18 uterine, 19 and gastric cancer. 20 We have noticed high levels of serum CA-125 in patients with LAM during standard clinical testing. Because CA-125 has been used as a marker of ovarian cancer and because the patient study population was predominantly female, high levels of serum CA-125 may be a source of concern to patients with LAM and their physicians. Serum CA-125 levels may also be of clinical utility for monitoring LAM diagnosis, progression, or treatment.
We hypothesized that serum CA-125 levels might be elevated and associated with disease progression in patients with LAM and that sirolimus treatment could decrease CA-125 levels.
Patients and Methods

Patient Cohort and Statistical Analysis
Research subjects were enrolled in the LAM protocol (95-H-0186; approved by the institutional review board of the National Heart, Lung, and Blood Institute) and provided written informed consent. Diagnoses of LAM in 241 patients were confirmed by histopathologic findings or the presence of cystic disease by CT scan, plus TSC, AMLs, high vascular endothelial growth factor D (VEGF-D) levels, and/or LLMs or chylous effusions. Patients were excluded if their medical records revealed other malignancies or ovarian cysts. CA-125 serum levels were measured in a Clinical Laboratory Improvement Amendmentsapproved laboratory, using the Abbott AxSYM automated serological analyzer or Immulite analyzer (Siemens); levels > 34 U/mL were considered elevated. Values determined by Immulite were converted to AxSYM-compatible values. Patient records were reviewed for clinical phenotypes. Pulmonary function testing was performed as described. 21 VEGF-D testing was performed at the Translational Core Laboratories, Cincinnati Children's Hospital.
The distribution of CA-125 values was skewed to the right (with some very high measurements); to minimize the effect of these high numbers, the CA-125 data were log-transformed. All measurements from multiple visits per subject were considered. Mixed effects models were used to identify factors associated with CA-125 levels. Variables identified in a univariate analysis as significantly associated with CA-125 at P < .10 were considered for inclusion in the multivariate model. Variables included age, time of follow-up from initial visit, FEV 1 , diffusing capacity for carbon monoxide (DLCO), AML, menopausal status, TSC diagnosis, lymphatic involvement (ie, ascites, pleural effusions, adenopathy, chylous effusions, and/or LLMs), and pleural effusions. Variables with P values # .05 remained in the model. SAS version 9.3 (SAS Institute, Inc) was used for all analyses.
Immunostaining of LAM Lung Tissue
Formalin-fixed, paraffin-embedded lung tissue sections were immunostained with the monoclonal antibody HMB45 (1:50; Dako) and/or anti-CA-125 antibodies (1:200; Santa Cruz Biotechnology) using an alkaline phosphatase procedure (Vectastain ABC-AP; Vector Laboratories) or hydrogen peroxidase/diaminobenzidine kit (Spring Bioscience), following manufacturer's directions.
Frozen or formalin-fixed, paraffin-embedded LAM lung tissue sections were immunostained by using an indirect fluorescent immunostaining technique as described previously. 22 Anti-CA-125 (1:50) and anti-asmooth muscle actin (a-SMA) (1:100; Abcam) antibodies were paired with Texas Red anti-mouse IgG (1:200; Vector Laboratories) or sheep polyclonal anti-rabbit IgG fluorescein isothiocyanate (1:200; Abcam Inc), respectively. Sections were stained with 4 0 ,6-diamidino-2-phenylindole. A Zeiss LSM 510 META laser scanning confocal microscope equipped with 405 diode, argon, and helium-neon laser sources, using a Plan Neofluar 40X oil objective, was used to inspect the lung sections.
Results
Serum CA-125 and Clinical Correlations
We examined levels of CA-125 in serum from patients with LAM. Because serum CA-125 levels are known to be elevated in cancers, patients who had malignancies such as breast, 17 lung, 18 uterine, 19 ovarian, 10 and gastric cancer were excluded from the study cohort. 20 Also excluded were measurements from patients while taking sirolimus (so as not to confound the initial study with effects of the drug). CA-125 values were in the normal range (# 34 U/mL) for 181 of 241 patients (75.1%) for all visits ( Fig 1A) . Sixty patients (24.9%) had at least one above-normal serum CA-125 measurement (>34 U/mL) ( Fig 1B) , and 17 of these 60 patients had above-normal serum CA-125 levels at every visit. Univariate analysis, examining CA-125 levels as a continuous variable, revealed a correlation between higher serum CA-125 levels and decreased pulmonary function (percent predicted FEV 1 : P < .001; DLCO: P < .001). Patients with LAM and higher serum CA-125 levels were younger and premenopausal (P ¼ .044 and P ¼ .001, respectively). Some associations were maintained in the multivariate analysis (FEV 1 : P < .001; menopause: P < .001) (Fig 2A , Table 1 ). Percent predicted DLCO was also a significant predictor of CA-125 levels in the multivariate model (P ¼ .022), but the presence of DLCO as a co-predictor decreased the effect of FEV 1 (P ¼ .005), and the model performance did not improve with its addition.
Univariate analysis determined that the presence of TSC in 48 patients with LAM had no effect on serum CA-125 level ( Table 1 ). The presence of AMLs was also not associated with CA-125 serum levels. Univariate analysis revealed that higher serum levels of CA-125 were associated with lymphatic involvement, as defined by ascites, pleural effusions, adenopathy, chylous effusions, and/or LLMs, in patients with LAM (P < .001) and with pleural effusions alone (P < .001); pleural effusions remained a predictive factor of CA-125 levels in the multivariate analysis (P < .001) (Fig 2B) . Of the 17 patients with above-normal serum CA-125 levels at every visit, 15 (88.2%) had a history of pleural effusions. Chest radiographs or CT scans were available for 77 of the visits by these 15 patients, and 59 (76.6%) of the scans revealed the presence of pleural effusions at the same visit the above-normal serum CA-125 levels were detected.
Serum CA-125 Levels in Therapy
Thirty-two patients with LAM were undergoing sirolimus treatment. Serum CA-125 levels were measured in patients who were taking sirolimus for at least two consecutive visits and with at least one visit prior to initiation of sirolimus therapy. Patients were followed an average of 4.4 years prior to sirolimus treatment and an average of 3.4 years (range, 6 months-9 years) on treatment. Data showed that treatment with sirolimus was associated with decreased serum CA-125 levels (P ¼ .002) (Fig 3) . Of the 32 patients taking sirolimus, 17 never had above-normal levels of CA-125, either prior to or following treatment. Nine patients had many visits with CA-125 levels > 65 U/mL; CA-125 levels in these patients decreased with sirolimus treatment but did not necessarily fall to < 34 U/mL. 
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Interestingly, all nine patients had chylous pleural effusions that diminished or resolved with sirolimus treatment.
CA-125 and VEGF-D in Therapy
VEGF-D is a biomarker used for the diagnosis of LAM; serum levels > 800 pg/mL, along with cystic changes in the lung, are diagnostic for LAM. 23 Serum VEGF-D is also a marker of response to sirolimus. 24 Of the 32 aforementioned patients taking sirolimus, serum VEGF-D levels were measured in 23 (Fig 4) . Two patients never had VEGF-D levels greater than the diagnostic threshold of 800 pg/mL, and 12 never had CA-125 levels greater than the cutoff of 34 U/mL. Figure 4 also shows levels of VEGF-D over time with sirolimus treatment for six of the nine patients with pleural effusions and higher levels of CA-125. Serum VEGF-D levels seem to be a more informative marker than serum CA-125 levels.
CA-125 Expression in LAM Nodules
Immunohistochemical analysis of LAM lung tissue showed CA-125 within the LAM lung nodule adjacent to cells reactive to HMB45, a LAM cell marker 25 ( Figs 5A , 5B), and in the bronchial epithelial cells in "normal" tissue areas of LAM lung (Fig 5C) . CA-125 expression was evident in hyperplastic type II pneumocytes (Fig 5D) . In a univariate analysis, with cancer antigen 125 (CA-125) as a continuous variable, higher serum CA-125 levels were significantly associated with lower percent predicted FEV 1 (P < .001) and diffusing capacity for carbon monoxide (DLCO) (P < .001), younger age (P < .044), premenopause (P ¼ .001), lymphatic involvement (P < .001), and pleural effusions (P < .001). Tuberous sclerosis complex (TSC) and the presence of angiomyolipomas (AMLs) were not significantly associated with serum CA-125 levels. After multivariate analysis considering the variables associated with CA-125 levels, higher CA-125 levels were significantly associated with lower percent predicted FEV 1 (P < .001), premenopause (P < .001), and a history of pleural effusion (P < .001). Percent predicted DLCO was also a significant predictor of CA-125 level in the multivariate model (P ¼ .022), but its presence in the model reduced the effect of FEV 1 (P ¼ .005). Correlations were found across the whole study population; patients in this table were grouped into categories for illustrative purposes only. Data on pleural effusion history are unavailable for two patients.
chestjournal.org to the mesothelial epithelium. 32 In pancreatic cancer cells, co-expression of MUC16 and mesothelin upregulates MMP-7, promoting cell motility and invasion. 33 MUC16 binding to galectin-1 facilitates the export of galectin-1 to the cell surface, 34 where it mediates migration and invasion through hypoxiainducible factor 1a-mTOR signaling in renal cell carcinoma cell lines. 35 Thus, CA-125 could play a role in LAM cell dissemination.
Ninety-nine percent of healthy volunteers have serum CA-125 levels < 35 U/mL. Although 5% of patients with nonmalignant conditions and 28% with nonovarian malignancies have above-normal serum CA-125 levels, only 50% of patients with early-stage ovarian cancer have high levels of serum CA-125. 36 Therefore, CA-125 has both poor specificity and sensitivity for detecting ovarian cancer. CA-125 may be more useful as a biomarker for ovarian cancer prognosis and for monitoring response to therapy.
In the present study, we found that almost 25% of patients with LAM had at least one above-normal serum CA-125 level over multiple visits (Fig 1) . Seventeen chestjournal.org patients had above-normal CA-125 levels at all visits, with 15 having a history of pleural effusions and demonstration of pleural effusions according to scans in 76.6% of these visits. Similarly, nine patients receiving sirolimus treatment had pleural effusions that diminished or resolved with treatment, along with decreases in serum CA-125 levels. Serum CA-125 levels were associated with FEV 1 , menopause status, and pleural effusions in a multivariate analysis. However, the CA-125 association with FEV 1 was not a causative one. In an alternative analysis in which FEV 1 was considered as an outcome, pleural effusions were a significant predictor of FEV 1 (P ¼ .036; adjusted for initial FEV 1 value), whereas CA-125 levels were not (P ¼ .165; adjusted for initial FEV 1 ).
CA-125 is detected in pleura, peritoneum, and pericardium epithelia. A study of patients with chronic renal failure divided the subjects into those with and those without fluid in serosal cavities. Those patients with serosal fluid had markedly higher serum levels of CA-125 than those without serosal fluid, leading to the conclusion that serum CA-125 could be a biomarker for irritation of the pericardium, peritoneum, or pleura. 37 This conclusion was also reached by studies examining patients with ovarian cancer with pleural effusions 38 or ascites, 39 a patient with lymphoma and ascites, 40 a patient with sarcoidosis and ascites, 41 and patients with liver cirrhosis 39, 42 or hepatocellular carcinoma with ascites. 39 It is likely that the elevated serum CA-125 levels seen in the patients with LAM with pleural effusions are attributable to irritation of the pleura itself. Because sirolimus has been shown to reduce or resolve pleural effusions, 8, 43 a decrease in serum CA-125 levels for patients taking sirolimus may be due to its effect on the pleura and pleural effusions. Although the involvement of the pleura may account for some of the high levels of CA-125, two of the 17 patients with high serum CA-125 levels at every visit had no evidence of pleural effusions, and of the 60 patients with at least one elevated CA-125 level, 30 (50.0%) had no history of pleural effusions. In these cases, the LAM nodule may be the source of CA-125.
Serum VEGF-D is the best biomarker to date for diagnosis of LAM and to follow LAM progression and treatment. 24 Interestingly, VEGF-D levels associate with lymphatic involvement (LLMs and adenopathy) 44 similar to the association of CA-125 with lymphatic involvement. In the present study, we found that although CA-125 levels were associated with disease progression and treatment, the percentage of patients with elevated CA-125 levels was probably not large enough to be a more useful biomarker than VEGF-D. It is important to note, however, that high levels of CA-125 can be detected in patients with LAM, especially those with pleural effusions, and that these levels do not necessarily indicate the presence of other cancers such as ovarian cancer.
Conclusions
We explored the clinical utility of CA-125 as a biomarker in LAM and examined the molecule in LAM tissues and disease. We found high levels of serum CA-125 in almost 25% of patients with LAM. High levels of CA-125 were associated with worse percent predicted FEV 1 and the presence of pleural effusions. Levels of serum CA-125 decrease with sirolimus treatment, perhaps reflecting both a direct effect on the LAM nodule, which expresses CA-125, and an indirect effect on pleural effusions.
